CN101808987A - 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 - Google Patents

作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 Download PDF

Info

Publication number
CN101808987A
CN101808987A CN200880018820A CN200880018820A CN101808987A CN 101808987 A CN101808987 A CN 101808987A CN 200880018820 A CN200880018820 A CN 200880018820A CN 200880018820 A CN200880018820 A CN 200880018820A CN 101808987 A CN101808987 A CN 101808987A
Authority
CN
China
Prior art keywords
difluorophenyl
pyrrolidin
chloro
fluorophenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880018820A
Other languages
English (en)
Chinese (zh)
Inventor
C·索尼森
L·斯万森
F·彼德松
N·瓦特斯
S·瓦特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NSAB Filial af Neurosearch Sweden AB
Original Assignee
NSAB Filial af Neurosearch Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSAB Filial af Neurosearch Sweden AB filed Critical NSAB Filial af Neurosearch Sweden AB
Publication of CN101808987A publication Critical patent/CN101808987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880018820A 2007-06-05 2008-06-04 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 Pending CN101808987A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94199407P 2007-06-05 2007-06-05
SE0701387 2007-06-05
SE0701387-3 2007-06-05
US60/941,994 2007-06-05
PCT/EP2008/056915 WO2008148801A2 (en) 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
CN101808987A true CN101808987A (zh) 2010-08-18

Family

ID=39743744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880018820A Pending CN101808987A (zh) 2007-06-05 2008-06-04 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷

Country Status (16)

Country Link
US (1) US8188301B2 (https=)
EP (1) EP2155671B8 (https=)
JP (1) JP5444535B2 (https=)
KR (1) KR20100038295A (https=)
CN (1) CN101808987A (https=)
AU (1) AU2008258599B2 (https=)
BR (1) BRPI0812740A2 (https=)
CA (1) CA2690091A1 (https=)
CO (1) CO6251288A2 (https=)
IL (1) IL202045A0 (https=)
MX (1) MX2009012787A (https=)
NZ (1) NZ581364A (https=)
RU (1) RU2471781C2 (https=)
UA (1) UA98783C2 (https=)
WO (1) WO2008148801A2 (https=)
ZA (1) ZA200908592B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107646031A (zh) * 2015-05-20 2018-01-30 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
CN110621659A (zh) * 2017-05-19 2019-12-27 综合研究实验室瑞典股份公司 (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CA2744308C (en) 2008-11-24 2017-05-30 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
MX2011005034A (es) 2008-11-24 2011-06-16 Nsab Af Neurosearch Sweden Ab Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical.
EP2367786B1 (en) * 2008-11-24 2013-01-09 NSAB, Filial af NeuroSearch Sweden AB, Sverige Novel 1 -alkyl- 3 -hydroxy- 3 -phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
WO2010071575A1 (en) * 2008-12-16 2010-06-24 Astrazeneca Ab Quaternary piperidine derivatives and uses thereof
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
WO2017138588A1 (ja) 2016-02-10 2017-08-17 住友化学株式会社 １－メチルピロリジン－３－オールの製造方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) * 1959-03-17 Substituted amino alcohols
DE1144279B (de) 1957-09-26 1963-02-28 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols
BE704683A (https=) 1966-11-07 1968-02-15
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
US5128362A (en) * 1988-01-15 1992-07-07 Abbott Laboratories 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
DE3802175A1 (de) 1988-01-26 1989-08-03 Hoechst Ag N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5444083A (en) * 1989-02-03 1995-08-22 Eisai Co., Ltd. Pyrrolidine compound and pharmaceutical use
WO1992018475A2 (en) * 1991-04-17 1992-10-29 The Upjohn Company Substituted phenylazacycloalkanes as cns agents
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
EP1098892A1 (en) 1998-07-20 2001-05-16 MERCK PATENT GmbH Biphenyl derivatives
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
DE19840611A1 (de) * 1998-09-05 2000-03-09 Klaus Wanner GABA-uptake-Inhibitoren mit Pyrrolidinstruktur
AU5025600A (en) 1999-05-17 2000-12-05 Foxboro Company, The Process control configuration system with parameterized objects
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7700587B2 (en) * 2004-09-07 2010-04-20 Florida A&M University Haloperidol analogs
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
WO2007053145A1 (en) 2005-11-04 2007-05-10 Florida A & M University Haloperidol analogs
CA2626220A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
AU2008258597A1 (en) 2007-06-05 2008-12-11 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107646031A (zh) * 2015-05-20 2018-01-30 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
CN107646031B (zh) * 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物
CN110621659A (zh) * 2017-05-19 2019-12-27 综合研究实验室瑞典股份公司 (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途
CN110621659B (zh) * 2017-05-19 2023-02-28 综合研究实验室瑞典股份公司 (+)-3-(2,3-二氟苯基)-3-甲氧基吡咯烷或其药学上可接受的盐、其制备方法及其用途

Also Published As

Publication number Publication date
NZ581364A (en) 2011-10-28
US8188301B2 (en) 2012-05-29
US20100179211A1 (en) 2010-07-15
WO2008148801A3 (en) 2009-01-29
AU2008258599B2 (en) 2013-06-13
RU2009143104A (ru) 2011-07-20
EP2155671B1 (en) 2017-12-20
IL202045A0 (en) 2010-06-16
WO2008148801A2 (en) 2008-12-11
BRPI0812740A2 (pt) 2016-07-19
CA2690091A1 (en) 2008-12-11
JP2010529081A (ja) 2010-08-26
JP5444535B2 (ja) 2014-03-19
EP2155671B8 (en) 2018-02-21
KR20100038295A (ko) 2010-04-14
CO6251288A2 (es) 2011-02-21
EP2155671A2 (en) 2010-02-24
ZA200908592B (en) 2011-02-23
AU2008258599A1 (en) 2008-12-11
WO2008148801A8 (en) 2009-12-10
MX2009012787A (es) 2009-12-15
UA98783C2 (en) 2012-06-25
RU2471781C2 (ru) 2013-01-10

Similar Documents

Publication Publication Date Title
CN101808987A (zh) 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
JP4488891B2 (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
EP2486005B1 (en) Pyrrolidine gpr40 modulators
CN106061964B (zh) 能够刺激神经发生的n-苯基-内酰胺衍生物及其在神经性病症的治疗中的用途
CN102224136B (zh) 用作皮质儿茶酚胺能神经传递调节剂的3-苯基-3-甲氧基-吡咯烷衍生物
KR20090028654A (ko) 포타슘 채널의 기능을 조절하는 아민 유도체, 그의 제조방법 및 용도
EP0626373B1 (en) Quinazolinone derivatives
EP1963268B1 (en) Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
CN101711234A (zh) 作为皮层儿茶酚胺能神经传递调节剂的新型二取代的苯基吡咯烷
CN109963834B (zh) 可用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
JPH10500698A (ja) カルシウムチャンネルアンタゴニストとしてのフェノキシアルキル置換ピペリジン、ピロリジン、モルホリンおよびチオモルホリン
HK1147260A (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CN107646031A (zh) 用作皮质儿茶酚胺能神经传递调节剂的新型氮杂环丁烷衍生物
EP2155729B1 (en) Prolinamide-tetrazole derivatives as nk3 receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1147260

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20100818

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1147260

Country of ref document: HK